Form 4: Xenon Pharmaceuticals CEO Executes Stock Option and Sells Shares Under 10b5-1 Plan

Xenon Pharmaceuticals' CEO, Ian Mortimer, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Ian Mortimer, the President and CEO of Xenon Pharmaceuticals, executed stock options to acquire common shares at a price of $17.76 per share.
• Concurrently, Mr. Mortimer sold a portion of these shares on the open market at prices ranging from approximately $40.00 to $41.145 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 27, 2024.
• The transactions occurred over several days, from January 23, 2025, to January 27, 2025.
• The total number of shares sold was 55,000, while the number of shares acquired through option exercises was 55,000.
• Following these transactions, Mr. Mortimer directly owns 31,302 common shares and indirectly owns 14,300 shares through his spouse.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan. It is neither particularly positive nor negative.

Positives

• The CEO's exercise of stock options indicates confidence in the company's future prospects.
• The sales were conducted under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of insider trading.

Negatives

• The sale of shares by the CEO, even under a 10b5-1 plan, could be perceived negatively by some investors.

Risks

• The market may react negatively to the CEO selling shares, even if it is part of a pre-planned strategy.
• There is a risk that the stock price could be affected by these transactions.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to manage these transactions. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical sector such as Vertex Pharmaceuticals and BioMarin Pharmaceutical.
• The reported price range for the sale of shares is within the typical range for executive stock sales, which often occur after a vesting period or option exercise.
• The volume of shares sold is not unusual for a CEO's transactions, and the fact that it was done under a pre-arranged plan is consistent with industry best practices.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, but the pre-planned nature of the transactions should mitigate any negative impact.
• Employees may view the CEO's stock activity as a sign of confidence or a routine financial transaction.

Key Dates

Keywords

insider trading, stock options, share sales, Rule 10b5-1, Xenon Pharmaceuticals, Ian Mortimer, executive compensation